Decoy Therapeutics Inc. 8-K

What Happened Decoy Therapeutics Inc. (DCOY) filed an 8-K on April 2, 2026 announcing it received Nasdaq notice of noncompliance with the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2). The company requested a Nasdaq Hearings Panel review, presented a plan at a February 6, 2026 hearing and implemented a reverse stock split effective March 6, 2026 (trading split-adjusted beginning March 9, 2026). The Hearings Panel granted an exception period through March 20, 2026; the stock closed at $7.47 on March 20, demonstrating compliance by trading above $1.00 for 10 consecutive business days. On March 31, 2026 the Hearings Panel confirmed the company has regained compliance. As required by Nasdaq rule, Decoy will remain subject to a Mandatory Panel Monitor until March 31, 2027. The filing also includes standard forward-looking statements and cautions about risks, including potential future noncompliance or delisting.

Key Details

• Nasdaq noncompliance notice under Rule 5550(a)(2) for sub-$1.00 closing bid over 30 consecutive business days.
• Reverse stock split effective March 6, 2026; shares began trading on a split-adjusted basis March 9, 2026.
• Hearings Panel granted an exception through March 20, 2026; common stock closed at $7.47 on March 20, meeting the 10-business-day $1.00 requirement.
• Company will be subject to a Mandatory Panel Monitor until March 31, 2027.

Why It Matters Regaining compliance preserves Decoy’s listing on The Nasdaq Capital Market, which maintains liquidity and market access for shareholders. However, the Mandatory Panel Monitor and the company’s recent history of noncompliance are ongoing governance/monitoring matters investors should note. The reverse split may have reduced outstanding share count and affected per-share metrics; investors should review recent filings (8-K, 10-K, 10-Q) for details on the split ratio and any other impacts.